Literature DB >> 11018688

Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications.

E P Diamandis1, G M Yousef, A R Soosaipillai, L Grass, A Porter, S Little, G Sotiropoulou.   

Abstract

BACKGROUND: The human kallikrein gene family has contributed the best prostatic biomarkers currently available, including prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2). Recently, new members of the human kallikrein gene family have been identified. One new member is the KLK6 gene, encoding for human kallikrein 6 (hK6), which is also known as zyme/protease M/neurosin. In this paper, we describe development of antibodies and a sensitive immunofluorometric procedure for hK6 protein.
METHODS: Recombinant hK6 protein was used as immunogen to develop polyclonal antibodies in rabbits and mice. These antibodies were used to develop a sandwich-type time-resolved immunofluorometric procedure for hK6.
RESULTS: The newly developed hK6 immunofluorometric assay has a detection limit of 0.5 microg/L and upper concentration range of 200 microg/L. The assay is highly specific (no detectable cross-reactivity from PSA and hK2) and was used to quantify hK6 protein in various biologic fluids. Highest concentrations of hK6 were found in milk of lactating women, cerebral spinal fluid, nipple aspirate fluid, and breast cyst fluid. hK6 was also detected in male and female serum, in the majority of seminal plasmas and in a small fraction of amniotic fluids and breast tumor cytosols. hK6 was not detectable in urine. Chromatographic studies indicated that hK6 is present in these biologic fluids in its free, 30-kDa form.
CONCLUSIONS: This is the first reported sensitive immunofluorometric procedure for quantifying hK6 protein. hK6 is a secreted proteolytic enzyme that is found at high levels in cerebrospinal fluid and all breast secretions. This assay will facilitate further studies to examine the possible application of hK6 in diagnostics, including cancer and neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018688     DOI: 10.1016/s0009-9120(00)00145-4

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  27 in total

1.  Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.

Authors:  Jin Ju Kim; Jong-Tae Kim; Hyo Ran Yoon; Min Ah Kang; Joo Heon Kim; Young-Ha Lee; Jae Wha Kim; Seon-Jin Lee; Eun Young Song; Pyung Keun Myung; Hee Gu Lee
Journal:  Tumour Biol       Date:  2012-02-29

2.  Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.

Authors:  Jane Bayani; Paula Marrano; Cassandra Graham; Yingye Zheng; Lin Li; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Jeremy A Squire; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2010-08-11       Impact factor: 6.603

3.  Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Authors:  Cynthia Kuk; Vathany Kulasingam; C Geeth Gunawardana; Chris R Smith; Ihor Batruch; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2008-12-01       Impact factor: 5.911

4.  Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system.

Authors:  Uros Kuzmanov; Nianxin Jiang; Christopher R Smith; Antoninus Soosaipillai; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2008-12-16       Impact factor: 5.911

5.  Quantification of Human Kallikrein-Related Peptidases in Biological Fluids by Multiplatform Targeted Mass Spectrometry Assays.

Authors:  Theano D Karakosta; Antoninus Soosaipillai; Eleftherios P Diamandis; Ihor Batruch; Andrei P Drabovich
Journal:  Mol Cell Proteomics       Date:  2016-07-01       Impact factor: 5.911

Review 6.  α-Synuclein and protein degradation systems: a reciprocal relationship.

Authors:  Maria Xilouri; Oystein Rod Brekk; Leonidas Stefanis
Journal:  Mol Neurobiol       Date:  2012-09-02       Impact factor: 5.590

7.  Temporal trajectory of biofluid markers in Parkinson's disease.

Authors:  Min Seok Baek; Myung Jun Lee; Han-Kyeol Kim; Chul Hyoung Lyoo
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

8.  Combined panel of serum human tissue kallikreins and CA-125 for the detection of epithelial ovarian cancer.

Authors:  Stephen Chee Liang Koh; Chan Yiong Huak; Delfi Lutan; Johny Marpuang; Suwiyoga Ketut; Nyoma Gede Budiana; Agustria Zainu Saleh; Mohamad Farid Aziz; Hariyono Winarto; Heru Pradjatmo; Nguyen Khac Han Hoan; Pham Viet Thanh; Mahesh Choolani
Journal:  J Gynecol Oncol       Date:  2012-07-02       Impact factor: 4.401

9.  KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.

Authors:  N M A White; M Mathews; G M Yousef; A Prizada; C Popadiuk; J J E Doré
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

10.  Early detection biomarkers for ovarian cancer.

Authors:  Sreeja Sarojini; Ayala Tamir; Heejin Lim; Shihong Li; Shifang Zhang; Andre Goy; Andrew Pecora; K Stephen Suh
Journal:  J Oncol       Date:  2012-12-23       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.